BC Week In Review | Apr 5, 2019
Company News

EspeRare, Dermelix to develop in utero therapy for rare disease

Dermelix partnered with the EspeRare Foundation to develop DMX-101 for X-linked hypohydrotic ectodermal dysplasia, a rare pediatric genetic disease. The partners plan to begin a pivotal study of the protein replacement therapy next half in...
BC Innovations | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Jan 4, 2018
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and mouse studies suggest inhibiting EDA could help treat obesity-related insulin resistance. In obese patients and a mouse model of obesity, liver expression of EDA was higher than in healthy volunteers...
Items per page:
1 - 3 of 3